Claude M. Wischik

University of Aberdeen — United Kingdom

Medicine · Health Sciences

47h-index10.7kcitations186works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(124), Prion Diseases and Protein Misfolding(35), Cholinesterase and Neurodegenerative Diseases(31), Neuroscience and Neuropharmacology Research(25), Dementia and Cognitive Impairment Research(21)

Publications185 total

Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer’s disease
Behavioural Pharmacology·2025· 1 citedOpen Access
Inhibiting Disulfide Bonding in Truncated Tau297–391 Results in Enhanced Self-Assembly of Tau into Seed-Competent Assemblies
ACS Chemical Neuroscience·2025Open Access
Role of <sup>18</sup>F‐florzolotau PET in diagnostic and therapeutic decision‐making for cognitive impairment
Alzheimer s & Dementia·2025· 2 citedOpen Access
A key region of Tau that is able to drive assembly and modulate inhibition by Hydromethylthionine
Journal of Molecular Biology·2025Open Access
FDG-PET Image Classification in Alzheimer’s Disease: from Traditional Visual Analysis to Advanced Transfer Learning
Nuclear Medicine and Molecular Imaging·2025· 2 cited
Inhibiting disulphide bonding in truncated tau297-391 results in enhanced self-assembly of tau into seed-competent assemblies
2025
Obtaining personalized predictions from a randomized controlled trial on Alzheimer’s disease
Scientific Reports·2025Open Access
A Key Region of Tau that Drives Assembly and Modulates Inhibition by Hydromethylthionine
SSRN Electronic Journal·2025Open Access
Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia
Brain Research Bulletin·2024· 4 citedOpen Access
Author response for "Hydromethylthionine sustains truncated tau‐dependent inflammation‐lowering effects in mouse brain"
2024
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease
Alzheimer s Research & Therapy·2024· 7 citedOpen Access
Personalized Predictions from Population Level Experiments: A Study on Alzheimer's Disease
arXiv (Cornell University)·2024· 1 citedOpen Access
Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model
Cells·2024· 10 citedOpen Access
Solubility of α-synuclein species in the L62 mouse model of synucleinopathy
Scientific Reports·2024· 1 citedOpen Access
A Meta-Analysis on Presynaptic Changes in Alzheimer’s Disease
Journal of Alzheimer s Disease·2023· 13 citedOpen Access
Back‐translation of clinical tau‐aggregation inhibitor trials to experimental models: negative interactions of dementia therapies
Alzheimer s & Dementia·2023Open Access
Significant dose‐dependent reduction in neurofilament light chain concentration in plasma with oral tau aggregation inhibitor hydromethylthionine mesylate
Alzheimer s & Dementia·2023· 2 citedOpen Access
Causal association of cardiovascular risk factors with Alzheimer’s disease
Alzheimer s & Dementia·2023Open Access
Apathy-like behaviour in tau mouse models of Alzheimer’s disease and frontotemporal dementia
Behavioural Brain Research·2023· 12 citedOpen Access
Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
International Journal of Molecular Sciences·2023Open Access
page 1 of 10Next →

Frequent Co-authors

Charles R. Harrington(32), John M. D. Storey(11), M Novák(8), Patricia C. Edwards(8), Martin Roth(8), John H. Xuereb(7), Peter Bentham(5), Damon Wischik(5), Roger T. Staff(5), Gernot Riedel(5), Elizabeta B. Mukaetova‐Ladinska(5), Carol Brayne(5), Felicia A. Huppert(5), Eugene S. Paykel(5), Janet E. Rickard(5), R. Anthony Crowther(4), A. Klug(4), Ross Jakes(4), César Milstein(4), Karin A. Kook(4)